Aurobindo Pharma Limited (BOM:524804)
1,247.80
+59.70 (5.02%)
At close: Apr 23, 2025
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 79.79B INR in the quarter ending December 31, 2024, with 8.53% growth. This brings the company's revenue in the last twelve months to 309.22B, up 10.85% year-over-year. In the fiscal year ending March 31, 2024, Aurobindo Pharma had annual revenue of 290.02B with 16.68% growth.
Revenue (ttm)
309.22B
Revenue Growth
+10.85%
P/S Ratio
2.36
Revenue / Employee
11.89M
Employees
26,015
Market Cap
730.53B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
Mar 31, 2021 | 247.75B | 16.76B | 7.26% |
Mar 31, 2020 | 230.99B | 35.35B | 18.07% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,627.08B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,409.52B |
Infosys | 1,647.16B |
Bajaj Finance | 358.05B |
Aurobindo Pharma News
- 9 days ago - Aurobindo Pharma gains over 2.5% after USFDA nod for Rivaroxaban tablets in $8.5 billion US market - Business Upturn
- 9 days ago - Top stocks to watch today, April 15: HDFC Bank, Tata Power, Cyient, IRCON, Vedanta, Aurobindo Pharma and more - Business Upturn
- 9 days ago - Stocks to watch today: Zydus, Aurobindo, HCL Tech, Tata Power, Indian Hotels, Cyient in focus on expansion and global deals - Business Upturn
- 13 days ago - Aurobindo Pharma subsidiary receives 11 USFDA observations after North Carolina facility inspection - Business Upturn
- 13 days ago - Aurobindo Pharma shares surge over 3% as subsidiary CuraTeQ Biologics reports successful trial results for bone drug BP16 - Business Upturn
- 13 days ago - Top stocks to watch today, April 11: Tata Steel, Infosys, TCS, BHEL, Aurobindo Pharma, Biocon and more - Business Upturn
- 15 days ago - Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’ - Business Upturn
- 19 days ago - Aurobindo Pharma subsidiary secures EU approval for Dyrupeg, a pegylated filgrastim biosimilar - Business Upturn